Show simple item record

dc.contributor.authorEl-Salhy, Magdhy
dc.contributor.authorGilja, Odd Helge
dc.contributor.authorHatlebakk, Jan Gunnar
dc.date.accessioned2024-12-05T08:07:09Z
dc.date.available2024-12-05T08:07:09Z
dc.date.created2024-10-02T10:11:21Z
dc.date.issued2024
dc.identifier.issn1286-4579
dc.identifier.urihttps://hdl.handle.net/11250/3168472
dc.description.abstractThe long-term effects of the transplant dose, its administration route and repeated faecal microbiota transplantation (FMT) on the outcomes of FMT for patients with irritable bowel syndrome (IBS) are unknown. This study included 171 patients (125 females and 46 males): 90 g of donor feces was administered into the large intestine (LI) in 58, into the small intestine (SI) in 57, and into the SI twice (repeated SI) in 56. The patients provided a fecal sample and completed five questionnaires at the baseline and at 2 years after FMT. Fecal bacteria and the dysbiosis index were analyzed using 16S rRNA gene PCR DNA amplification/probe. The response rates at 2 years after FMT were 47.2%, 80.9%, and 76.6% in the LI, SI, and repeated-SI groups, respectively. The response rate was significantly higher in the SI and repeated SI groups than in the LI group. IBS symptoms at 2 years after FMT were less severe in the SI and repeated-SI groups than in the LI group. Fluorescent signals of several bacteria were significantly correlated with IBS symptoms and fatigue after FMT. No long-term adverse events were observed. In conclusion, administering the transplant to the SI increased the long-term response rate and reduced IBS symptom severity compared with administering it to the LI, and led to the long-term colonization of beneficial bacteria. There was no long-term difference between one and two FMT procedures (www.clinicaltrials.gov: NCT04236843).en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleFactors underlying the long-term efficacy of faecal microbiota transplantation for patients with irritable bowel syndromeen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.source.articlenumber105372en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.micinf.2024.105372
dc.identifier.cristin2308595
dc.source.journalMicrobes and infectionen_US
dc.identifier.citationMicrobes and infection. 2024, 26, 105372.en_US
dc.source.volume26en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal